Short Bowel Syndrome (SBS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Short Bowel Syndrome (SBS) Marketed and Pipeline Drugs Report Overview

Short bowel syndrome (SBS) is defined as a condition in which poor absorption of required nutrients from foods occurs due to a lack of sufficient length of the small intestine. SBS usually occurs when portions of the small intestine have been surgically removed due to various underlying conditions like inflammatory bowel disease (IBD), cancer, traumatic injuries, and blood clots in the arteries that supply blood to the intestine. In rare cases, the condition could also be due to congenital defects (portions of the small intestine missing or damaged at birth). Approximately 94,106 diagnosed prevalent cases of SBS are anticipated in 2023 in the 16 major markets (16MM) covered in GlobalData’s epidemiology forecast for SBS.

The SBS marketed and pipeline drugs market research offers a competitive landscape combining data from the pharma intelligence center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. This report provides a data-driven overview of the current and future competitive landscape in SBS therapeutics.

Leading Marketed Drugs in Short Bowel Syndrome (SBS)

A few of the leading marketed drugs in SBS are teduglutide – Revestive/Gattex, (acetaminophen + drotaverine) – Drotin Plus, and (glutamine + sodium gualenate) – Marzulene S among others. The therapeutic management of SBS comprises a variety of medications mainly aiming for increased adaptation/rehabilitation of the lining (mucosa) of the intestines. The marketed drugs space for SBS mainly includes hormonal therapy (somatropin), GLP-2R agonist (teduglutide), and HRH2 blockers (cimetidine).

Top Sponsors in the SBS Marketed and Pipeline Drugs Market

A few of the top sponsors in the SBS marketed and pipeline drugs market are Shire Pharmaceuticals International UC, Zealand Pharma AS, VectivBio Holding AG, 9 Meters Biopharma Inc, Mayo Clinic, Takeda Pharmaceuticals Co Ltd, and Jaguar Health Inc among others.

SBS Marketed and Pipeline Drugs Sponsors Analysis

Buy the full Report for More SBS Marketed and Pipeline Drugs Sponsor Insights, Download a Free Report Sample

Short Bowel Syndrome Marketed Drugs Segmentation by Mechanism of Action

The key mechanisms of action for SBS-marketed drugs are receptor antagonist, receptor agonist, enzyme inhibitor, ligand replacement, and ligand sequestrant. The most prominent mechanism of action for most marketed drugs for SBS is receptor antagonist.

Short Bowel Syndrome Marketed Drugs Analysis by MoA

Buy the full Report for More MoA Insights into Short Bowel Syndrome Marketed Drugs, Download a Free Report Sample

Short Bowel Syndrome Marketed Drugs Segmentation by Routes of Administration

The key routes of administration for Short Bowel Syndrome marketed drugs are oral and injection. Most marketed drugs for SBS are by the oral RoA.

Short Bowel Syndrome Marketed Drugs Analysis by RoA

Buy the full Report for More RoA Insights into Short Bowel Syndrome Marketed Drugs, Download a Free Report Sample

Short Bowel Syndrome Marketed Drugs Segmentation by Molecule Type

The key molecule types in the SBS marketed drugs market are small molecule, biologics, and polymer. Most of the marketed drugs in the SBS market fall under the small molecule category.

Short Bowel Syndrome Marketed Drugs Analysis by Molecule Type

Buy the full Report for More Molecule Type Insights into Short Bowel Syndrome Marketed Drugs, Download a Free Report Sample

The key mechanisms of action for SBS pipeline drugs are receptor agonist and ion channel blocker. Most of the SBS pipeline drugs MoA are receptor agonist.

Short Bowel Syndrome Pipeline Drugs Analysis by MoA

Buy the full Report for More MoA Insights into Short Bowel Syndrome Pipeline Drugs, Download a Free Report Sample

Short Bowel Syndrome Pipeline Drugs Segmentation by Routes of Administration

The key routes of administration for Short Bowel Syndrome pipeline drugs are injection and oral. The pipeline drugs for SBS are mostly by injection, followed by oral.

Short Bowel Syndrome Pipeline Drugs Analysis by RoA

Buy the full Report for More RoA Insights into Short Bowel Syndrome Pipeline Drugs, Download a Free Report Sample

Short Bowel Syndrome Pipeline Drugs Segmentation by Molecule Type

Most of the pipeline drugs for SBS are biologics, followed by small molecule.

Short Bowel Syndrome Pipeline Drugs Analysis by Molecule Types

Buy the full Report for More Molecule Type Insights into Short Bowel Syndrome Pipeline Drugs, Download a Free Report Sample

SBS Marketed and Pipeline Drugs Market – Deals Landscape

• On 27th October 2022, Huons Global to Enter into Agreement with Lotte Biologics.
• On 31st March 2022, Quadri Pharma Enters into Licensing Agreement with Jaguar Health.

Buy the full Report for More SBS Marketed and Pipeline Drugs Deal Insights, Download a Free Report Sample

Segments Covered in the Report

SBS Marketed Drugs Mechanisms of Action Outlook (Number of Drugs)

• Receptor Antagonist
• Receptor Agonist
• Enzyme Inhibitor
• Ligand Replacement
• Ligand Sequestrant.

SBS Marketed Drugs Routes of Administration Outlook (Number of Drugs)

• Oral
• Injection

SBS Marketed Drugs Molecule Type Outlook (Number of Drugs)

• Small Molecule
• Biologic
• Polymer

SBS Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs)

• Receptor Agonist
• Ion Channel Blocker

SBS Pipeline Drugs Routes of Administration Outlook (Number of Drugs)

• Oral
• Injection

SBS Pipeline Drugs Molecule Types Outlook (Number of Drugs)

• Small Molecule
• Biologic

Scope

GlobalData’s Short Bowel Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the AC market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AC market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.